Company intelligence / Profile preview

Dermolastin

Scottsdale, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Dermolastin is a biotechnology company focused on the development of recombinant human elastin for medical and aesthetic applications. The company leverages its proprietary platform to produce bio-identical human elastin, a critical protein responsible for skin elasticity that naturally diminishes with age. Dermolastin's pipeline targets wound healing, scar prevention, and skin rejuvenation. By restoring elastin levels, the company aims to provide therapeutic solutions for dermatological conditions and age-related skin degradation.

Therapeutic areas: Dermatology
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Dermolastin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermolastin.

Explore the full profile